In the months of July and August the whole healthcare sector recorded a positive stock market trend. But it lost ground in September, ending the third quarter in line with general market indices. In the third quarter of 2021 the share of BB Biotech it expressed a performance of -3.3% in Swiss francs and -2.0% in euros. For the first nine months of the year this translates into a total return (including dividend) of 18.2% in Swiss francs and 19.0% in euros.
As an early adopter investor, BB Biotech used Moderna’s strength on the fundamentals level to take targeted profits, but maintained its position in the stock. After eleven years, the management team closed the position in Halozyme, making a profit of $ 235 million. A major part of these resources has flowed into companies with an interesting oncology pipeline, including Revolution Medicines, Relay Therapeutics, Fate Therapeutics, Essa Pharma, Macrogenics, Molecular Templates and Mersana Therapeutics.
#Stock #market #vaccine #recall #investments #healthcare #sector #growing